Aims: Cutaneous benign fibrohistiocytic tumours are among the most common soft tissue lesions. Their biological nature, in particular whether they are neoplastic or reactive, has long been disputed. Some morphological subtypes can be confused with sarcoma. Since available karyotypic data in these lesions are scarce, this study was undertaken to determine whether their cytogenetic analysis might demonstrate clonality and might help in differential diagnosis.
Methods And Results: Thirteen karyotyped benign cutaneous fibrous histiocytomas (BFH) were morphologically reassessed and classified as ordinary BFH (eight cases), cellular BFH (four cases), and one ankle-type lesion. Five cases (38%) showed clonal cytogenetic changes, although the aberrations varied and did not correlate with histological subtypes. Karyotypic aberrations were more common in cellular BFH (3/4) than in the ordinary BFH (2/8).
Conclusions: The demonstration of clonal chromosome abnormalities, in at least some cases, supports the neoplastic nature of cutaneous BFH. The karyotypic changes identified are different from those in dermatofibrosarcoma, with which cellular BFH is often confused histologically.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2559.2000.00947.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Colocalization of Cancer-Associated Biomarkers on Single Extracellular Vesicles for Early Detection of Cancer.
J Mol Diagn
December 2024
Mercy BioAnalytics Inc., Waltham, Massachusetts.
Detection of cancer early, when it is most treatable, remains a significant challenge because of the lack of diagnostic methods sufficiently sensitive to detect nascent tumors. Early-stage tumors are small relative to their tissue of origin, heterogeneous, and infrequently manifest in clinical symptoms. The detection of early-stage tumors is challenging given the lack of tumor-specific indicators (ie, protein biomarkers, circulating tumor DNA) to enable detection using a noninvasive diagnostic assay.
View Article and Find Full Text PDFImproving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle-Based Blood Test: Performance in a Training and Verification Cohort.
J Mol Diagn
December 2024
MRC Clinical Trials Unit, Institute for Clinical Trials and Methodology, University College London, London, United Kingdom.
Article Synopsis
- - The Mercy Halo Ovarian Cancer Test (OC Test) is a new screening method that detects ovarian cancer by analyzing proteins found on tumor-associated extracellular vesicles in blood, aiming for both high sensitivity and specificity.
- - In a study involving 397 women, the OC Test showed impressive results: 97% specificity and sensitivity for high-grade serous carcinoma (HGSC), and it also identified 73.5% of non-HGSC ovarian cancer cases.
- - Compared to the conventional cancer antigen 125, the OC Test resulted in fewer false positives among patients with non-cancerous conditions, indicating its potential for effective ovarian cancer screening.
Influence of membrane on the antigen presentation of the HIV-1 envelope membrane proximal external region (MPER).
Curr Opin Struct Biol
October 2024
Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 87545, USA. Electronic address:
The membrane proximal external region (MPER) of the HIV envelope glycoproteins has generated renewed interest after a recent phase I vaccine trial that presented MPER lipid-peptide epitopes demonstrated promise to elicit a broad neutralization response. The antigenicity of MPER is intimately associated with the membrane, and its presentation relies significantly on the lipid composition. This review brings together recent findings on the influence of membranes on the conformation of MPER and its recognition by broadly neutralizing antibodies.
View Article and Find Full Text PDFComparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.
J Virol
September 2024
Department of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA.
Nucleoside-modified mRNA technology has revolutionized vaccine development with the success of mRNA COVID-19 vaccines. We used modified mRNA technology for the design of envelopes (Env) to induce HIV-1 broadly neutralizing antibodies (bnAbs). However, unlike SARS-CoV-2 neutralizing antibodies that are readily made, HIV-1 bnAb induction is disfavored by the immune system because of the rarity of bnAb B cell precursors and the cross-reactivity of bnAbs targeting certain Env epitopes with host molecules, thus requiring optimized immunogen design.
View Article and Find Full Text PDFVaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.
Cell
June 2024
Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunobiology, Duke School of Medicine, Durham, NC 27710, USA; Duke Global Health Institute, Duke School of Medicine, Durham, NC 27710, USA. Electronic address:
A critical roadblock to HIV vaccine development is the inability to induce B cell lineages of broadly neutralizing antibodies (bnAbs) in humans. In people living with HIV-1, bnAbs take years to develop. The HVTN 133 clinical trial studied a peptide/liposome immunogen targeting B cell lineages of HIV-1 envelope (Env) membrane-proximal external region (MPER) bnAbs (NCT03934541).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!